Catalent: EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6
EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of contract drug manufacturer Catalent (CTLT.N), according to a filing on the European Commission website on Monday.The post EU antitrust regulators to rule on Novo's Catalent buy by Dec. 6 appeared first on PharmaLive.
Read full article »
Catalent is a New Jersey-based multinational company that provides services including drug development and clinical trial for pharmaceutical and consumer healthcare companies.
Read more